Last reviewed · How we verify
FSH-IBSA
FSH-IBSA is a recombinant human follicle-stimulating hormone (FSH) that stimulates ovarian follicle development and estrogen production in women undergoing fertility treatment.
FSH-IBSA is a recombinant human follicle-stimulating hormone (FSH) that stimulates ovarian follicle development and estrogen production in women undergoing fertility treatment. Used for Ovulation induction in women with anovulation or oligo-ovulation undergoing assisted reproductive technology, Controlled ovarian hyperstimulation in in vitro fertilization (IVF) cycles.
At a glance
| Generic name | FSH-IBSA |
|---|---|
| Sponsor | IBSA Institut Biochimique SA |
| Drug class | Gonadotropin |
| Target | FSH receptor (FSHR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | Phase 3 |
Mechanism of action
FSH-IBSA binds to FSH receptors on granulosa cells in the ovary, promoting follicle growth and maturation during assisted reproductive technology cycles. This leads to increased estrogen production and development of multiple mature oocytes suitable for retrieval and fertilization.
Approved indications
- Ovulation induction in women with anovulation or oligo-ovulation undergoing assisted reproductive technology
- Controlled ovarian hyperstimulation in in vitro fertilization (IVF) cycles
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/discomfort
- Nausea
Key clinical trials
- Pharmacokinetics of FSH and hCG Following Multiple Dose of Gonadotropins-IBSA. (PHASE1)
- Pharmacokinetics of FSH and hCG After a Single Subcutaneous Injection of Gonadotropins-IBSA (PHASE1)
- Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol
- The Difference Between POSEIDON Group 3 and Group 4 as Regards IVF
- The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian Syndrome (NA)
- Controlled Ovarian Hyperstimulation (COH) With Sequential HPFSH & HMG Versus Rec-F.S.H Alone in ICSI Cycle
- Growth Hormone Co-treatment Within a GnRH Antagonist Protocol in Patients With Poor Ovarian Response (PHASE2)
- Extended Letrozole Regimen Co-treatment With Gonadotropin Releasing Hormone Antagonist Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Poor Responders Undergoing IVF-ET (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FSH-IBSA CI brief — competitive landscape report
- FSH-IBSA updates RSS · CI watch RSS
- IBSA Institut Biochimique SA portfolio CI